Pfizer

News

EU regulators slap safety restriction on Pfizer's Xeljanz

European safety regulators have placed restrictions on Pfizer’s Xeljanz, saying it should not be used in the higher dose in some patients with ulcerative colitis because of concerns of incr

News

Pfizer selects first GPCR candidate from Sosei Heptares tie-...

Pfizer has selected the first drug candidate from a collaboration with Sosei Group to develop drugs for major diseases, which are aimed at targets from the G protein-coupled receptor (GPCR)

News

Pfizer acquires Therachon and its dwarfism drug

Pfizer has announced it will pay $340 million upfront to snap up rare disease biotech Therachon, which is developing treatments for a form

News

Pfizer claims FDA okay for rare heart disease drug tafamidis

The FDA has given a green light to two formulations of Pfizer’s tafamidis that have become the first drugs to be approved in the US for cardiomyopathy associated with rare disease transthyr

Views & Analysis

Collaborating to fight NASH

Eric Hughes, Global Development Unit head at Novartis for Immunology, Hepatology & Dermatology, believes that collaboration is going to be key to finally finding a treatment for non

News

Pfizer/Lilly non-opioid pain drug shows more positive result...

Results from a new study of Pfizer and Lilly’s non-opioid pain drug tanezumab have shown that it can be effective in osteoarthritis in higher doses, but lower doses remain ineffective and the dr

EU regulators slap safety restriction on Pfizer's Xeljanz

Pfizer selects first GPCR candidate from Sosei Heptares tie-...

Pfizer acquires Therachon and its dwarfism drug

Pfizer claims FDA okay for rare heart disease drug tafamidis

Collaborating to fight NASH

Pfizer/Lilly non-opioid pain drug shows more positive result...

ASCO 2026: Quality of life, not just quantity, with Dr Harol...

Discover a new era of healthcare panel engagement: Grounded ...

Pfizer

Editor's Picks